Abstract

Transition-metal nanomaterials are very important to non-enzymatic glucose sensing because of their excellent electrocatalytic ability, good selectivity, the fact that they are not easily interfered with by chloride ion (Cl−), and low cost. However, the linear detection range needs to be expanded. In this paper, Cu2O–bovine serum albumin (BSA) core-shell nanoparticles (NPs) were synthesized for the first time in air at room temperature by a facile and green route. The structure and morphology of Cu2O–BSA NPs were characterized. The as-prepared Cu2O–BSA NPs were used to modify the glassy carbon electrode (GCE) in a Nafion matrix. By using cyclic voltammetry (CV), the influence from scanning speed, concentration of NaOH, and load of Cu2O–BSA NPs for the modified electrodes was probed. Cu2O–BSA NPs showed direct electrocatalytic activity for the oxidation of glucose in 50 mM NaOH solution at 0.6 V. The chronoamperometry result showed this constructing sensor in the detection of glucose with a lowest detection limit of 0.4 μM, a linear detection range up to 10 mM, a high sensitivity of 1144.81 μAmM−1cm−2 and reliable anti-interference property to Cl−, uric acid (UA), ascorbic acid (AA), and acetaminophen (AP). Cu2O–BSA NPs are promising nanostructures for the fabrication of non-enzymatic glucose electrochemical sensing devices.

Highlights

  • Diabetes mellitus is a group of lifelong metabolic diseases characterized by hyperglycemia caused by multiple causes

  • To control blood sugar concentration, people must monitor blood sugar frequently, so blood sugar detection plays a vital role in the treatment of diabetes mellitus

  • The present study indicates that 2D and 3D graphene–Cu2 O composites have promising applications in the fabrication of non-enzymatic electrochemical sensing devices

Read more

Summary

Introduction

Diabetes mellitus is a group of lifelong metabolic diseases characterized by hyperglycemia caused by multiple causes. According to the International Diabetes Federation (IDF) [1], in 2017, there is one diabetic patient for every 11 people aged 20–79, and 425 million people suffering from diabetes worldwide. It is estimated that the number of diabetic patients in this age group will rise to 629 million by 2045. To control blood sugar concentration, people must monitor blood sugar frequently, so blood sugar detection plays a vital role in the treatment of diabetes mellitus. This encourages researchers to explore the field of glucose biosensors

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call